Literature DB >> 20463797

Analyses of ERG in a patient with intraocular lymphoma.

Chieko Yasuda1, Shinji Ueno, Mineo Kondo, Nagako Kondo, Chang-Hua Piao, Hiroko Terasaki.   

Abstract

PURPOSE: To follow the changes in the electroretinograms (ERGs) in a patient with primary intraocular lymphoma (PIOL) who had a complete remission after chemotherapy.
METHODS: ERGs were recorded in a 41-year-old woman with PIOL during and after complete remission with chemotherapy. The patient was diagnosed with PIOL from both the ocular signs and the medical history of cranial lymphoma.
RESULTS: The ERGs were depressed in the subject. The amplitudes of the bright white flash b-waves were smaller than the a-waves, resulting in a "negative type" ERG. Six weeks after the beginning of chemotherapy, the ocular changes had resolved, and the ERGs, although not of the "negative type", still showed signs that the amplitude had not returned to normal levels.
CONCLUSION: The negative type ERGs indicated that the inner retina had been damaged to a greater extent than the outer retina. In the convalescent stage, when the ocular manifestations were resolved, the ERGs were still not fully recovered. Although only one case was studied, we suggest that ERGs can be used to evaluate and follow patients with a PIOL.

Entities:  

Keywords:  electroretinogram; primary intraocular lymphoma; uveitis masquerade syndrome

Year:  2010        PMID: 20463797      PMCID: PMC2861936          DOI: 10.2147/opth.s9618

Source DB:  PubMed          Journal:  Clin Ophthalmol        ISSN: 1177-5467


Introduction

A primary intraocular lymphoma (PIOL) is a subtype of primary non-Hodgkin’s lymphomas of the central nervous system in which the retina, vitreous, and/or optic nerve head may be involved.1–3 Patients with a PIOL typically present with a form of uveitis and vitritis that is unresponsive to corticosteroid therapy, thus the so-called uveitis masquerade syndrome. This can occur together with, or independently of, a primary cerebral nervous system lymphoma. The disease has a poor prognosis, and patients normally die as a result the growth of the cerebral lymphoma with a mean survival of 20 months from the diagnosis of the ocular disorder.4 As best we know, electroretinography (ERG) has not been used to follow the changes in retinal function during the course of PIOL. We present the changes in the ERGs during and after a complete remission of PIOL with chemotherapy.

Case report

The patient, a 41-year-old woman, had been diagnosed with a primary intracranial malignant lymphoma (non-Hodgkins, diffuse medium-sized B cell lymphoma) for three years. She presented with a 3-week history of blurred vision and photophobia, primarily in her right eye. Her best-corrected visual acuities were 20/60 OD and 20/20 OS. The intraocular pressure was normal in both eyes. Slit-lamp examination showed mild vitritis in the right eye, and ophthalmoscopy showed no abnormalities. After 3 weeks of observation the right fundus had developed whitish exudates, massive subretinal infiltration from a macular lesion, and slight swelling of the optic disc. Cells were detected in the anterior chamber, but the fundus of the left eye was normal (Figure 1). The Goldmann visual field of the right eye had a dense central relative scotoma, but was almost normal in the left eye (Figure 2).
Figure 1

Fundus photograph of the right A) and the left eyes B). The right fundus shows whitish exudates, massive subretinal infiltration under the macular lesion, and slight disc swelling. The left fundus is normal. Fluorescein angiography of the right C) and left eyes D) Slight leakage of fluorescein can be seen on the right optic disc. The left eye is normal. Optical coherence tomography of the macular area of the right E) and left eye F). Massive subretinal infiltration is present in the right eye. The left eye is normal.

Figure 2

Goldmann perimetry showing a central scotoma in the right eye. The visual field of left eye is normal.

Full-field ERGs were recorded according to International Society for Clinical Electrophysiology of Vision (ISCEV) standards.5 The scotopic, bright white, cone, and 30 Hz flicker ERGs 3 weeks after the initial visit are shown in Figure 3. The amplitudes of the different ERG components were reduced in both eyes, but to a greater extent in the right eye. The amplitude of the bright white flash b-waves was distinctly reduced, and was smaller than the a-waves, resulting in the “negative type” ERG in both eyes. This indicated that the functional depression was greater in the inner retina than the outer retina.6
Figure 3

Full-field ERGs (rod, bright white, cone and 30 Hz flicker) recorded according to International Society for Clinical Electrophysiology of Vision (ISCEV) standards. Compared to the normal ERGs, the amplitudes of all components were reduced especially in the right eye. Focal macular ERGs elicited by a 15 degree stimulus spot were recorded from both eyes (bottom row). A marked reduction of amplitude can be seen in the right eye.

Focal macular ERGs were recorded to assess macular function as described in Miyake et al.7 The ERG from the right eye was almost nonrecordable, and that of left eye was about one-half the normal amplitude (Figure 3; Focal macular ERGs). Because of the rapid decrease in the visual acuity of the right eye to 20/600, and the increasing retinal infiltration and exudations since the previous examination, diagnostic vitrectomy was performed (Figure 4). Cytological examination of the vitreal specimen did not show any abnormal lymphocytes or monocytes, in addition to which flow cytometry did not show monoclonality. The cytokine analysis was negative without a specific increase in the IL10/IL6 ratio. Although the results of the cytological examinations were negative, a primary intraocular lymphoma was strongly suspected.
Figure 4

Fundus photograph after vitrectomy of the right eye. The retinal infiltrates and exudates have progressed in the right eye within one week since the previous examination. The left eye fundus had no abnormality.

Eight weeks after the first visit, chemotherapy with cyclophosphamide, cytosine arabinoside, etoposide, and dexamethasone was started. Four days after the treatment, the visual symptoms and ophthalmoscopic appearance of the fundus improved. Six weeks after beginning chemotherapy, her best-corrected visual acuity improved to 20/20 in both eyes. The ocular lesions were completely resolved, leaving atrophic pigmentary changes (Figure 5). A relative central scotoma still remained in the right eye, but the visual field sensitivity had improved. The cells in the anterior chamber of the left eye had also disappeared.
Figure 5

Fundus photography of the right A) and the left eye B) one month after chemotherapy. The ocular lesions have completely resolved leaving atrophic pigmentary changes. Optical coherence tomography of the macular area of the right C) and the left eye D) shows that the massive subretinal infiltration of the right eye has disappeared.

Although the rod and cone components of the full-field ERGs had improved after chemotherapy, the amplitudes had still not reached normal limits (Figure 6). The recovery of the b-wave was greater than that of the a-wave in the bright flash ERG, and so the waveform was not of the “negative type” at this point.
Figure 6

Full field ERGs (rod, bright white, cone and 30 Hz flicker) and focal macular ERG recorded one month after chemotherapy. The ERG amplitudes of all components have increased after therapy but still remained smaller than normal ERGS in both eyes.

Three years after the therapy, the patient had no evidence of systemic disease or recurrence of the PIOL. The ERGs were greatly improved but the amplitudes had still not reached the normal range.

Discussion

We have followed a patient with a PIOL by electroretinography, who went into complete remission after chemotherapy. We found that the bright flash ERGs were the negative-type ERGs before chemotherapy. These ERG findings suggest that the inner retina was damaged more than the outer retina. As a differential diagnosis, we suspected endophthalmitis and uveitis, especially Beçhet’s disease. However, from the history of intracranial malignant lymphoma, and the clinical signs, we diagnosed the patient as having a PIOL, even though the vitreous biopsy did not detect any malignant cells or a change in the IL-10/IL-6 ratio. It is known that the interpretation of vitreous specimens is sometimes difficult, and more than 40% of vitrectomy specimens may be nondiagnostic. 8,3 After chemotherapy, the b-wave recovered more quickly than the a-wave. These results indicate that the inner retinal damage was transient, and may have resulted from secondary inflammation due to the presence of tumor cells. In the convalescent stage, when the ocular manifestations were resolved, both full-field and focal macular ERGs were still not fully recovered. Earlier histopathological studies of PIOL’s have mentioned an infiltration of malignant lymphoma cells into the subretinal space, which would be detected as whitish exudates, and could also lead to damage to the retina.9,10 In our case, a marked prolongation of the focal macular ERG in the right eye may have been as a result of photoreceptor damage caused by just such subretinal infiltration.

Conclusion

In conclusion, we recorded ERGs from a patient whose ocular findings and history indicated that she had PIOL. The full-field ERGs were reduced in the right eye, showing a the negative-type ERG. After chemotherapy, there was a recovery in both the ocular signs and the ERGs. Although our conclusions are based on only one case, we recommend that ERGs be used to diagnose and follow patients with a PIOL.
  10 in total

Review 1.  Masquerade syndromes: malignancies mimicking inflammation in the eye.

Authors:  Tony Tsai; Joan M O'Brien
Journal:  Int Ophthalmol Clin       Date:  2002

2.  Standard for clinical electroretinography (2004 update).

Authors:  Michael F Marmor; Graham E Holder; Mathias W Seeliger; Shuichi Yamamoto
Journal:  Doc Ophthalmol       Date:  2004-03       Impact factor: 2.379

3.  Congenital stationary night blindness with negative electroretinogram. A new classification.

Authors:  Y Miyake; K Yagasaki; M Horiguchi; Y Kawase; T Kanda
Journal:  Arch Ophthalmol       Date:  1986-07

4.  Clinical features, laboratory investigations, and survival in ocular reticulum cell sarcoma.

Authors:  L N Freeman; A P Schachat; D L Knox; R G Michels; W R Green
Journal:  Ophthalmology       Date:  1987-12       Impact factor: 12.079

Review 5.  Variations in the presentation of primary intraocular lymphoma: case reports and a review.

Authors:  M K Gill; L M Jampol
Journal:  Surv Ophthalmol       Date:  2001 May-Jun       Impact factor: 6.048

Review 6.  Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features.

Authors:  Sarah E Coupland; Heinrich Heimann; Nikolaos E Bechrakis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-10-29       Impact factor: 3.117

Review 7.  Intraocular lymphoma.

Authors:  Chi-Chao Chan; Ronald R Buggage; Robert B Nussenblatt
Journal:  Curr Opin Ophthalmol       Date:  2002-12       Impact factor: 3.761

Review 8.  Intraocular lymphoma: update on diagnosis and management.

Authors:  Chi-Chao Chan; Dana J Wallace
Journal:  Cancer Control       Date:  2004 Sep-Oct       Impact factor: 3.302

9.  Evaluation of vitrectomy specimens and chorioretinal biopsies in the diagnosis of primary intraocular lymphoma in patients with Masquerade syndrome.

Authors:  Sarah E Coupland; Nikolaos E Bechrakis; Gerasimos Anastassiou; Andreas M H Foerster; Arnd Heiligenhaus; Uwe Pleyer; Michael Hummel; Harald Stein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-09-30       Impact factor: 3.117

10.  Asymmetry of focal ERG in human macular region.

Authors:  Y Miyake; N Shiroyama; M Horiguchi; I Ota
Journal:  Invest Ophthalmol Vis Sci       Date:  1989-08       Impact factor: 4.799

  10 in total
  4 in total

1.  Unilateral retinopathy secondary to occult primary intraocular lymphoma.

Authors:  Gaetano R Barile; Aakriti Garg; Donald C Hood; Brian Marr; Shafinaz Hussein; Stephen H Tsang
Journal:  Doc Ophthalmol       Date:  2013-10-01       Impact factor: 2.379

2.  Electrophysiological Monitoring of Focal and Entire Retinal Function during Treatment with Intravitreal Methotrexate for Intraocular Lymphoma.

Authors:  Takashi Matsushima; Yuji Yoshikawa; Airi Shimura; Ayana Yajima; Yui Ojima; Kei Shinoda
Journal:  Case Rep Ophthalmol       Date:  2021-04-30

Review 3.  Multimodal diagnostic imaging in primary vitreoretinal lymphoma.

Authors:  Lucy T Xu; Ye Huang; Albert Liao; Casey L Anthony; Alfredo Voloschin; Steven Yeh
Journal:  Int J Retina Vitreous       Date:  2022-08-26

4.  Changes of fundus autofluorescence and spectral-domain optical coherence tomographic findings after treatment of primary intraocular lymphoma.

Authors:  Mariko Egawa; Yoshinori Mitamura; Yuki Hayashi; Kentaro Semba; Takeshi Naito
Journal:  J Ophthalmic Inflamm Infect       Date:  2014-02-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.